|Bid||4.0000 x 1300|
|Ask||4.5300 x 1000|
|Day's Range||4.1600 - 4.3650|
|52 Week Range||1.2400 - 4.7400|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2023 - Nov 06, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.60|
Subscribe to Yahoo Finance Plus to view Fair Value for AMRX
Key Insights Significantly high institutional ownership implies Amneal Pharmaceuticals' stock price is sensitive to...
BRIDGEWATER, N.J., September 06, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced it has received Abbreviated New Drug Application ("ANDA") approval from the U.S. Food and Drug Administration ("FDA") for calcium gluconate in sodium chloride injection, 1000 mg/50 mL and 2000 mg/100 mL. This injectable product is currently on the U.S. FDA shortage product list.
BRIDGEWATER, N.J., September 06, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced it has received its first product approval in China. Sevelamer carbonate was approved and is expected to launch shortly. In addition, the Company expects to launch oseltamivir phosphate in China this year as well, upon approval. In total, Amneal has 6 products pending review in China with more product registrations planned over time. Since 2019, the Company has collaborate